Compare Adaptive Biotechnologies Corp (ADPT) vs Matson Inc (MATX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Matson Inc — how do they compare? Adaptive Biotechnologies Corp trades at $20.12 (market cap $3.33B), while Matson Inc trades at $201.49 (market cap $6.01B). The key difference: Matson Inc is the larger of the two by market cap, and Matson Inc pays a 0.77% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | MATX | |
|---|---|---|
Market Cap | $3.33B | $6.01B |
Sector | Health | Technology |
52-Week High | $22.37 | $204.53 |
52-Week Low | $10.24 | $88.05 |
Enterprise Value | $3.19B | $6.61B |
Dividend Yield | — | 0.77% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Matson (MATX) trades at $204.53, up 0.49% with strong technical momentum near resistance at $206. The stock shows robust fundamentals with consistent earnings beats, a 12.92% net margin, and shareholder-friendly actions including dividend increases and share buybacks. Recent news highlights the company's niche Pacific shipping advantages and operational efficiency gains.
Outlook remains positive given analyst consensus (64% buy ratings) and strong profitability metrics, though risks include shipping rate volatility and macroeconomic sensitivity. The current valuation at 15.17x P/E appears reasonable for a company with double-digit ROE and dividend growth, positioning MATX as a quality mid-cap transportation play.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Matson Inc
Matson, Inc. is an American shipping and logistics company primarily operating in the Pacific. The company provides ocean transportation services, including container, automobile, and general cargo, particularly between the U.S. West Coast, Hawaii, Alaska, and Guam. Matson also offers logistics services, including warehousing, less-than-container load (LCL) consolidation, and supply chain management, making it a critical service provider for businesses operating across the Pacific region.
Read more on MATX →
